Trial Profile
A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 15 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Feb 2020 New trial record
- 26 Feb 2020 According to an Apeiron Biologics media release, data from this trial will be assessed to ascertain whether a Phase 2B clinical trial in a larger number of patients is warranted.